PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 04/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. VRCA, XLO, SPRO, RNTX, STTK, ATNM, ATRA, RVPH, LTRN, and BLUEShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Verrica Pharmaceuticals (VRCA), Xilio Therapeutics (XLO), Spero Therapeutics (SPRO), Rein Therapeutics (RNTX), Shattuck Labs (STTK), Actinium Pharmaceuticals (ATNM), Atara Biotherapeutics (ATRA), Reviva Pharmaceuticals (RVPH), Lantern Pharma (LTRN), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Verrica Pharmaceuticals Xilio Therapeutics Spero Therapeutics Rein Therapeutics Shattuck Labs Actinium Pharmaceuticals Atara Biotherapeutics Reviva Pharmaceuticals Lantern Pharma bluebird bio PHAXIAM Therapeutics (NASDAQ:PHXM) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation. Which has preferable valuation and earnings, PHXM or VRCA? PHAXIAM Therapeutics has higher revenue and earnings than Verrica Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM Therapeutics$32.66M0.32-$240KN/AN/AVerrica Pharmaceuticals$7.57M5.79-$67M-$1.54-0.31 Do analysts recommend PHXM or VRCA? Verrica Pharmaceuticals has a consensus price target of $9.50, suggesting a potential upside of 1,904.22%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer PHXM or VRCA? In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Verrica Pharmaceuticals and 1 mentions for PHAXIAM Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.93 beat PHAXIAM Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PHAXIAM Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PHXM or VRCA more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. PHAXIAM Therapeutics' return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A Verrica Pharmaceuticals -625.06%-591.84%-141.63% Do institutionals & insiders have more ownership in PHXM or VRCA? 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, PHXM or VRCA? PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Does the MarketBeat Community favor PHXM or VRCA? Verrica Pharmaceuticals received 167 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformPHAXIAM TherapeuticsN/AN/AVerrica PharmaceuticalsOutperform Votes16763.26% Underperform Votes9736.74% SummaryVerrica Pharmaceuticals beats PHAXIAM Therapeutics on 9 of the 15 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$124.06M$5.50B$7.98BDividend YieldN/A3.69%5.11%4.23%P/E RatioN/A3.2022.6318.59Price / Sales0.324,247.68398.09103.52Price / CashN/A13.0238.1834.62Price / Book0.3933.066.724.27Net Income-$240,000.00-$90.45M$3.22B$248.18M7 Day PerformanceN/A4.08%1.58%1.47%1 Month PerformanceN/A5.48%4.09%3.96%1 Year PerformanceN/A94.27%16.05%5.57% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049VRCAVerrica Pharmaceuticals4.1529 of 5 stars$0.46-2.0%$9.50+1,971.1%-93.3%$42.10M$7.57M-0.2540Gap UpXLOXilio Therapeutics3.5043 of 5 stars$0.79-2.0%$4.00+403.8%-26.4%$41.10M$6.34M-0.4670Gap DownSPROSpero Therapeutics4.3333 of 5 stars$0.73-0.7%$5.00+587.7%-53.7%$40.93M$27.40M10.39150Short Interest ↑RNTXRein TherapeuticsN/A$1.86+0.5%N/AN/A$40.91MN/A-0.609News CoverageGap DownSTTKShattuck Labs2.5582 of 5 stars$0.85-4.7%$7.50+781.0%-90.6%$40.78M$5.72M-0.56100Positive NewsATNMActinium Pharmaceuticals1.4167 of 5 stars$1.30-5.8%$7.40+469.2%-80.3%$40.56M$81,000.00-0.9430Analyst ForecastAnalyst RevisionATRAAtara Biotherapeutics4.0411 of 5 stars$6.90+2.4%$17.75+157.2%-53.7%$40.43M$128.94M-0.27330Upcoming EarningsPositive NewsRVPHReviva Pharmaceuticals2.797 of 5 stars$0.86+13.5%$10.00+1,059.2%-70.9%$40.32MN/A-0.785Short Interest ↑LTRNLantern Pharma2.488 of 5 stars$3.73+8.1%$25.00+570.2%-31.0%$40.23MN/A-2.1020Upcoming EarningsNews CoverageBLUEbluebird bio3.0043 of 5 stars$4.09-5.8%$44.60+990.5%-77.0%$40.04M$83.81M-0.11520Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Verrica Pharmaceuticals Competitors Xilio Therapeutics Competitors Spero Therapeutics Competitors Rein Therapeutics Competitors Shattuck Labs Competitors Actinium Pharmaceuticals Competitors Atara Biotherapeutics Competitors Reviva Pharmaceuticals Competitors Lantern Pharma Competitors bluebird bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHXM Stock Free PHXM Stock Alerts